| dc.contributor.author |
Pazaropoulos-Koot, Stella
|
|
| dc.contributor.author |
Mahommed, Safia
|
|
| dc.contributor.author |
Pienaar, Letitia
|
|
| dc.date.accessioned |
2026-05-08T06:17:56Z |
|
| dc.date.available |
2026-05-08T06:17:56Z |
|
| dc.date.issued |
2025-04 |
|
| dc.identifier.citation |
S Pazaropoulos-Koot, S Mahomed, L Pienaar South African Journal of Bioethics and Law 18 (1), 16-20, 2025 https://hdl.handle.net/10520/ejc-m_sajbl_v18_n1_a5 |
en_US |
| dc.identifier.issn |
1999-7639 |
|
| dc.identifier.uri |
https://ir.unisa.ac.za/handle/10500/32442 |
|
| dc.description.abstract |
Managing and treating rare diseases is a global concern, largely because of their rarity and the complexities associated with their care.Robust ethico-legal frameworks governing rare diseases are essential as they establish coordinated guidelines that ensure patients receivethe care and support which they require. This article examines and compares the existing frameworks for rare diseases in the UnitedKingdom and Italy, with those in South Africa (SA), highlighting the differences and similarities in how they operate, towards facilitatinga national framework that suits our context. The recommendations offer proposed solutions to add to the ongoing dialogue regardingthe current lack of governance for rare diseases in SA. The article further calls for a coherent national framework to better address andrepresent the needs and rights of individuals affected by rare diseases. SA requires a systematic approach, with clear guidelines fordiagnosing, treating and funding rare diseases. This approach would establish a basis for efficient resource allocation and equitable accessto essential treatments. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
South African Medical Association (SAMA) |
en_US |
| dc.subject |
Rare diseases |
en_US |
| dc.subject |
Prescribed Minimum Benefit |
en_US |
| dc.subject |
Medical Law |
en_US |
| dc.subject |
Healthcare |
en_US |
| dc.subject |
Medicine |
en_US |
| dc.subject |
National Health Insurance |
en_US |
| dc.subject |
Human Rights |
en_US |
| dc.subject |
Access to Healthcare |
en_US |
| dc.subject |
Orphan Drugs |
en_US |
| dc.title |
Facilitating a framework for managing rare diseases inSouth Africa: Comparative insights from the UK and Italy |
en_US |
| dc.type |
Article |
en_US |